George Y Wang
Examiner (ID: 4033)
Most Active Art Unit | 2871 |
Art Unit(s) | 2882, 2871 |
Total Applications | 215 |
Issued Applications | 148 |
Pending Applications | 11 |
Abandoned Applications | 56 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 17170439
[patent_doc_number] => 20210324109
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-21
[patent_title] => METHODS FOR CONTROLLING BLOOD PHARMACOKINETICS OF ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/359867
[patent_app_country] => US
[patent_app_date] => 2021-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17746
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17359867
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/359867 | METHODS FOR CONTROLLING BLOOD PHARMACOKINETICS OF ANTIBODIES | Jun 27, 2021 | Pending |
Array
(
[id] => 17299507
[patent_doc_number] => 20210395346
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => STEREOTYPIC NEUTRALIZING VH CLONOTYPES AGAINST SARS-COV-2 RBD IN COVID-19 PATIENTS AND THE HEALTHY POPULATION
[patent_app_type] => utility
[patent_app_number] => 17/353437
[patent_app_country] => US
[patent_app_date] => 2021-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26112
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 8
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17353437
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/353437 | STEREOTYPIC NEUTRALIZING VH CLONOTYPES AGAINST SARS-COV-2 RBD IN COVID-19 PATIENTS AND THE HEALTHY POPULATION | Jun 20, 2021 | Abandoned |
Array
(
[id] => 17299556
[patent_doc_number] => 20210395395
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => ENGINEERED IGA ANTIBODIES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/343232
[patent_app_country] => US
[patent_app_date] => 2021-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 81466
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17343232
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/343232 | ENGINEERED IGA ANTIBODIES AND METHODS OF USE | Jun 8, 2021 | Pending |
Array
(
[id] => 19339336
[patent_doc_number] => 12049514
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-30
[patent_title] => Anti-NME antibody and method of treating cancer or cancer metastasis
[patent_app_type] => utility
[patent_app_number] => 18/000249
[patent_app_country] => US
[patent_app_date] => 2021-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 58
[patent_figures_cnt] => 156
[patent_no_of_words] => 43014
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18000249
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/000249 | Anti-NME antibody and method of treating cancer or cancer metastasis | Jun 7, 2021 | Issued |
Array
(
[id] => 17815431
[patent_doc_number] => 11421030
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-08-23
[patent_title] => BTLA antibodies
[patent_app_type] => utility
[patent_app_number] => 17/330168
[patent_app_country] => US
[patent_app_date] => 2021-05-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 14
[patent_no_of_words] => 40134
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 198
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17330168
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/330168 | BTLA antibodies | May 24, 2021 | Issued |
Array
(
[id] => 17314510
[patent_doc_number] => 20210403558
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => ANTI-TIM-3 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-TIM-3 ANTIBODIES AND METHODS OF MAKING AND USING ANTI-TIM-3 ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/313511
[patent_app_country] => US
[patent_app_date] => 2021-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32835
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17313511
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/313511 | ANTI-TIM-3 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-TIM-3 ANTIBODIES AND METHODS OF MAKING AND USING ANTI-TIM-3 ANTIBODIES | May 5, 2021 | Abandoned |
Array
(
[id] => 18181147
[patent_doc_number] => 20230041876
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => BISPECIFIC ANTIBODY CONSTRUCTS FOR CDH3 AND CD3
[patent_app_type] => utility
[patent_app_number] => 17/306051
[patent_app_country] => US
[patent_app_date] => 2021-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48836
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17306051
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/306051 | Bispecific antibody constructs for CDH3 and CD3 | May 2, 2021 | Issued |
Array
(
[id] => 17243508
[patent_doc_number] => 20210363251
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-25
[patent_title] => T CELL RECRUITING POLYPEPTIDES BASED ON CD3 REACTIVITY
[patent_app_type] => utility
[patent_app_number] => 17/246771
[patent_app_country] => US
[patent_app_date] => 2021-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 61045
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17246771
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/246771 | T CELL RECRUITING POLYPEPTIDES BASED ON CD3 REACTIVITY | May 2, 2021 | Pending |
Array
(
[id] => 17052245
[patent_doc_number] => 20210261679
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/243362
[patent_app_country] => US
[patent_app_date] => 2021-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42971
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 108
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17243362
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/243362 | Anti-transferrin receptor antibodies and uses thereof | Apr 27, 2021 | Issued |
Array
(
[id] => 17482228
[patent_doc_number] => 20220089732
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-24
[patent_title] => ANTI-TIGIT ANTIBODIES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/240944
[patent_app_country] => US
[patent_app_date] => 2021-04-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 62828
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17240944
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/240944 | ANTI-TIGIT ANTIBODIES AND METHODS OF USE THEREOF | Apr 25, 2021 | Abandoned |
Array
(
[id] => 17533671
[patent_doc_number] => 20220112280
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-14
[patent_title] => TRANSPLANT TOLERANCE INDUCTION WITH CARBODIIMIDE TREATED TOLERIZING VACCINE
[patent_app_type] => utility
[patent_app_number] => 17/229534
[patent_app_country] => US
[patent_app_date] => 2021-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 74438
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17229534
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/229534 | TRANSPLANT TOLERANCE INDUCTION WITH CARBODIIMIDE TREATED TOLERIZING VACCINE | Apr 12, 2021 | Pending |
Array
(
[id] => 17007137
[patent_doc_number] => 20210238298
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-05
[patent_title] => NOVEL POLYPEPTIDES
[patent_app_type] => utility
[patent_app_number] => 17/229130
[patent_app_country] => US
[patent_app_date] => 2021-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45413
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 172
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17229130
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/229130 | Polypeptides | Apr 12, 2021 | Issued |
Array
(
[id] => 18526366
[patent_doc_number] => 11713352
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-01
[patent_title] => Immunotoxin for treating cancer
[patent_app_type] => utility
[patent_app_number] => 17/225953
[patent_app_country] => US
[patent_app_date] => 2021-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 27885
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17225953
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/225953 | Immunotoxin for treating cancer | Apr 7, 2021 | Issued |
Array
(
[id] => 16992238
[patent_doc_number] => 20210230658
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-29
[patent_title] => METHODS OF PROTEIN PRODUCTION
[patent_app_type] => utility
[patent_app_number] => 17/221378
[patent_app_country] => US
[patent_app_date] => 2021-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12743
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17221378
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/221378 | METHODS OF PROTEIN PRODUCTION | Apr 1, 2021 | Pending |
Array
(
[id] => 16991888
[patent_doc_number] => 20210230308
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-29
[patent_title] => CHIMERIC ANTIGEN RECEPTOR CELLS FOR TREATING SOLID TUMOR
[patent_app_type] => utility
[patent_app_number] => 17/220387
[patent_app_country] => US
[patent_app_date] => 2021-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30725
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17220387
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/220387 | Chimeric antigen receptor cells for treating solid tumor | Mar 31, 2021 | Issued |
Array
(
[id] => 17154954
[patent_doc_number] => 20210316005
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-14
[patent_title] => Detection and Treatment of Malignant Tumours in the CNS
[patent_app_type] => utility
[patent_app_number] => 17/220012
[patent_app_country] => US
[patent_app_date] => 2021-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28560
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17220012
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/220012 | Detection and Treatment of Malignant Tumours in the CNS | Mar 31, 2021 | Pending |
Array
(
[id] => 17126251
[patent_doc_number] => 20210301019
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-30
[patent_title] => BI-SPECIFIC FUSION PROTEINS FOR DEPLETION OF REGULATORY T CELLS
[patent_app_type] => utility
[patent_app_number] => 17/213588
[patent_app_country] => US
[patent_app_date] => 2021-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12646
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17213588
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/213588 | BI-SPECIFIC FUSION PROTEINS FOR DEPLETION OF REGULATORY T CELLS | Mar 25, 2021 | Pending |
Array
(
[id] => 17111821
[patent_doc_number] => 20210292418
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-23
[patent_title] => ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/204604
[patent_app_country] => US
[patent_app_date] => 2021-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34779
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17204604
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/204604 | ANTIBODIES | Mar 16, 2021 | Pending |
Array
(
[id] => 17363591
[patent_doc_number] => 11230608
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-01-25
[patent_title] => Anti-glycan antibodies and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/203650
[patent_app_country] => US
[patent_app_date] => 2021-03-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 7
[patent_no_of_words] => 6059
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 114
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17203650
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/203650 | Anti-glycan antibodies and uses thereof | Mar 15, 2021 | Issued |
Array
(
[id] => 16932473
[patent_doc_number] => 20210198362
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-01
[patent_title] => INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESIS
[patent_app_type] => utility
[patent_app_number] => 17/176096
[patent_app_country] => US
[patent_app_date] => 2021-02-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12598
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17176096
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/176096 | INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESIS | Feb 14, 2021 | Abandoned |